- Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo - - Unique broad mechanistic effect across…
This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.Vancouver,…
PARIS, FRANCE / ACCESSWIRE / July 18, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology…
Advancing Next-Generation Wearable Patient Engagement and Diagnostic Technology Designed to Enable More Efficient Detection of Eye DiseasesALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos…
Growth Sparks Excitement as STEMTECH Achieves Record-Breaking Surge in New Independent Business PartnersMIRAMAR, FL / ACCESSWIRE / July 17, 2023…
With a standard review, FDA set a PDUFA target action date of May 16, 2024FORT LEE, N.J., July 17, 2023…
CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 17, 2023 - IRLAB Therapeutics…
Figure 1 Acumen Pharmaceuticals, Inc. Figure 2 Acumen Pharmaceuticals, Inc.Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating…
PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused…